Hadas Reuveni

Keryx Biopharmaceuticals, Inc. engaged in the manufacture, development, and commercialization of medicines for use in treating human diseases. The company was founded in August 1, 2002 and was headquartered in Cambridge, MA.

AngioB Ltd. developed treatments for ischemic heart conditions. It also developed proprietary novel pro-angiogenic drugs to treat cardiovascular diseases and peripheral ischemic disorders. The company started in-vivo experiments to evaluate the pro-angiogenic potential of its lead compound in clinical-relevant models. AngioB was founded in July 2006 and was headquartered in Kiryat Shmona, Israel

NovoTyr Therapeutics Ltd. develops insulin-like growth factor receptor inhibitors. It provides services in the biotechnology, drug development, cancer and other proliferative disease sectors. The company was founded by Alexander Levitzki in 2005 and is headquartered in Kiryat Shmona, Israel

Tyrnovo Ltd. operates as a pharmaceutical company. It develops drugs that eliminates a key protein in cancer, resulting in improved cancer therapy, prevention of drug resistance, and increased life expectancy. The company was founded by Hadas Reuveni and is headquartered in Herzliya, Israel.